299 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Security National Bank

Security National Bank purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 299 shares of the pharmaceutical company’s stock, valued at approximately $125,000.

Several other institutional investors have also added to or reduced their stakes in VRTX. University of Texas Texas AM Investment Managment Co. purchased a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at $25,000. Arlington Trust Co LLC increased its holdings in shares of Vertex Pharmaceuticals by 97.1% in the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the period. ICA Group Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $28,000. Fortitude Family Office LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth $30,000. Finally, Baystate Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. BMO Capital Markets upped their target price on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, May 31st. Argus increased their price target on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the company a “buy” rating in a research note on Monday, June 17th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday. Finally, UBS Group lowered their target price on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $444.23.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs sold 7,073 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the sale, the director now directly owns 40,000 shares in the company, valued at $17,920,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 1,565 shares of the company’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $457.00, for a total value of $715,205.00. Following the sale, the chief executive officer now owns 121,374 shares of the company’s stock, valued at $55,467,918. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce I. Sachs sold 7,073 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the completion of the sale, the director now directly owns 40,000 shares in the company, valued at $17,920,000. The disclosure for this sale can be found here. Insiders have sold a total of 26,086 shares of company stock worth $11,983,266 over the last ninety days. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Up 0.0 %

VRTX stock traded up $0.18 during midday trading on Wednesday, reaching $474.00. 538,496 shares of the company were exchanged, compared to its average volume of 1,223,748. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. Vertex Pharmaceuticals Incorporated has a 1-year low of $335.82 and a 1-year high of $486.42. The company has a market cap of $122.32 billion, a price-to-earnings ratio of 30.79, a price-to-earnings-growth ratio of 2.43 and a beta of 0.41. The stock’s 50-day simple moving average is $440.20 and its 200 day simple moving average is $424.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $2.67 earnings per share. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.22 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.